Scarica l'app Stockscreener
203.49
1.37%
2.76
Dopo l'orario di chiusura:
204.93
1.44
+0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca stock gains 1.77% as bullish technicals and positive trial results fuel buying - Traders Union
AstraZeneca PLC stock: Positive liver cancer trial results spark investor interest - AD HOC NEWS
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import D - GuruFocus
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates - TipRanks
AstraZeneca climbs Thursday, outperforms market - marketwatch.com
Q1 2026 Dividend Check-In: Highest Quarterly Hike Percentage Since 2019 - Investing.com
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp - Insider Monkey
AstraZeneca reports positive phase III results for Imfinzi and Imjudo in liver cancer - Investing.com
AstraZeneca (NYSE: AZN) liver cancer combo boosts PFS in Phase III - Stock Titan
AstraZeneca PLCImfinzi+Imjudo improves PFS in early liver cancer - Research Tree
AstraZeneca’s Liver Cancer Treatment Shows Promise in Phase III Trial - AskTraders
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial - Reuters
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Canc - GuruFocus
ASTRAZENECA : Buy rating from JP Morgan - MarketScreener
Pictet North America Advisors SA Has $8.54 Million Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca plc Announces Positive High-Level Results from the Emerald-3 Phase III Trial - MarketScreener
AstraZeneca hails encouraging data for liver cancer drug regimen - London South East
AstraZeneca upbeat on results of liver cancer treatment trial - sharecast.com
AstraZeneca Says Liver Cancer Drug Combination Extends Progression-Free Survival in Phase 3 Trial - MarketScreener
AstraZeneca Reports Positive Phase III EMERALD-3 Results In Unresectable Liver Cancer - directorstalkinterviews.com
Deutsche Bank Maintains Sell on AstraZeneca (AZN) - Insider Monkey
Nordic Stocks in North AmericaAstraZeneca Gains 1.8 Percent - MarketScreener
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 18, 2026 - Meyka
AstraZeneca PLC Stock: Institutional Confidence Builds as Voting Rights Update Signals Stability for - AD HOC NEWS
AstraZeneca PLC Stock Gains Momentum on Positive Tozorakimab Phase 3 Data for COPD Treatment - AD HOC NEWS
Strong clinical milestones drive AstraZeneca stock higher despite mixed momentum readings - Traders Union
AstraZeneca updates total voting rights following admission of new shares - Investing.com
AstraZeneca (NYSE: AZN) updates voting rights and admits new shares - Stock Titan
AstraZeneca PLC Stock (AZN) Moved Up by 3.43% on Apr 1: Facts Behind the Movement - TradingKey
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results - proactiveinvestors.com
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa - Clinical Trials Arena
Moody Lynn & Lieberson LLC Increases Holdings in Astrazeneca Plc $AZN - MarketBeat
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
What's Going On With AstraZeneca Stock Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC Stock (AZN) Opened Up by 3.38% on Mar 31: Drivers Behind the Movement - TradingKey
AstraZeneca’s ALXN1850 On Blockbuster Trajectory Despite Mixed Phase III Results - Citeline News & Insights
Astrazeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia - Investing.com
ASTRAZENECA : Buy rating from Barclays - MarketScreener
AstraZeneca (AZN) Reports Positive Results from HPP Clinical Tri - GuruFocus
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus
ASTRAZENECA : JP Morgan maintains a Buy rating - MarketScreener
Eyes on Asia: Otsuka, Biogen, AstraZeneca - BioXconomy
ASTRAZENECA : Buy rating from Jefferies - MarketScreener
AstraZeneca says hypophosphatasia replacement enzyme trials positive - London South East
Boston Common Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca drug for rare bone disease shows positive trial results - Sharecast.com
ASTRAZENECA : Barclays remains its Buy rating - MarketScreener
Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
AstraZeneca PLC Stock: Positive Tozorakimab COPD Trial Results Drive Shares Higher Amid Strong Pipel - AD HOC NEWS
Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia - AstraZeneca
Deutsche Bank Maintains AstraZeneca(AZN.US) With Sell Rating, Cuts Target Price to $151.89 - Moomoo
AstraZeneca rises Monday, outperforms market - MarketWatch
AstraZeneca PLC Stock: Positive COPD Trial Results Bolster Growth Outlook for US-Listed Shares - AD HOC NEWS
US Urges Court to Toss AstraZeneca’s Drug Price Negotiation Suit - news.bloomberglaw.com
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients - Proactive financial news
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings - AOL.com
AstraZeneca PLC Stock (AZN) Opened Up by 5.70% on Mar 30: Key Drivers Unveiled - TradingKey
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies - TradingView
MOR Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN - MarketBeat
ASTRAZENECA : Deutsche Bank remains a Sell rating - marketscreener.com
Dakota Wealth Management Purchases 5,595 Shares of Astrazeneca Plc $AZN - MarketBeat
0.02%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):